Matthew Miessau

Matthew joined Epidarex as an Analyst in 2014. While at Epidarex Capital, Matthew has been actively involved in deal sourcing including expanding Epidarex Capital’s reach and relationships with key universities in emerging hubs in the US. He also focused on conducting due diligence on prospective investments on both sides of the Atlantic and portfolio management. Matthew also supports the firm’s fundraising efforts and LP reporting. Matthew is a Board Observer for AdoRx Therapeutics and Epidarex Exeed.

Prior to joining Epidarex, Matthew was the Program Manager for the Georgetown University Center for Drug Discovery where he was responsible for managing the daily financial and research operations for the Center as well as developing the Center’s annual budget and grant proposals.

Matthew is currently an instructor at the NIH Foundation for Advanced Education in the Sciences (FAES), teaching Biomedical Business Development for Scientists. In his role as an instructor he leverages his experience at Epidarex to provide real world insights to NIH researchers interested in learning about the commercialization of life science innovations.

Matthew holds an M.S. in Biotechnology and a B.S. in Biochemistry from Georgetown University.